Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

Randomised trial of pembrolizumab versus standard treatment in patients with...

Dr Kevin Harrington - Institute of Cancer Research, London, UK

Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Dr James Larkin - Royal Marsden Hospital, London, UK

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )

Non-randomised clinical trial aims to describe the safety and efficacy of...

Dr Richard Schilsky - University of Chicago, Chicago, USA

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs ( Dr Richard Schilsky - University of Chicago, Chicago, USA )

Transarterial chemoembolization with or without sorafenib for intermediate...

Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an...

Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma ( Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China )

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin...

Dr Merry-Jennifer Markham - University of Florida, Florida, USA

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )

Novel JAK inhibitor pacritinib proving effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Novel JAK inhibitor pacritinib proves effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Nivolumab shows highly promising activity in advanced liver cancer in early...

Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive...

Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )

Certain classes of genes in patients that could lead to prostate cancer

Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA

Certain classes of genes in patients that could lead to prostate cancer ( Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer